» Articles » PMID: 36091387

OcclusionChip: A Functional Microcapillary Occlusion Assay Complementary to Ektacytometry for Detection of Small-fraction Red Blood Cells with Abnormal Deformability

Overview
Journal Front Physiol
Date 2022 Sep 12
PMID 36091387
Authors
Affiliations
Soon will be listed here.
Abstract

Red blood cell (RBC) deformability is a valuable hemorheological biomarker that can be used to assess the clinical status and response to therapy of individuals with sickle cell disease (SCD). RBC deformability has been measured by ektacytometry for decades, which uses shear or osmolar stress. However, ektacytometry is a population based measurement that does not detect small-fractions of abnormal RBCs. A single cell-based, functional RBC deformability assay would complement ektacytometry and provide additional information. Here, we tested the relative merits of the OcclusionChip, which measures RBC deformability by microcapillary occlusion, and ektacytometry. We tested samples containing glutaraldehyde-stiffened RBCs for up to 1% volume fraction; ektacytometry detected no significant change in Elongation Index (EI), while the OcclusionChip showed significant differences in Occlusion Index (OI). OcclusionChip detected a significant increase in OI in RBCs from an individual with sickle cell trait (SCT) and from a subject with SCD who received allogeneic hematopoietic stem cell transplant (HSCT), as the sample was taken from normoxic (pO2:159 mmHg) to physiologic hypoxic (pO2:45 mmHg) conditions. Oxygen gradient ektacytometry detected no difference in EI for SCT or HSCT. These results suggest that the single cell-based OcclusionChip enables detection of sickle hemoglobin (HbS)-related RBC abnormalities in SCT and SCD, particularly when the HbS level is low. We conclude that the OcclusionChip is complementary to the population based ektacytometry assays, and providing additional sensitivity and capacity to detect modest abnormalities in red cell function or small populations of abnormal red cells.

Citing Articles

Motion blur microscopy: in vitro imaging of cell adhesion dynamics in whole blood flow.

Goreke U, Gonzales A, Shipley B, Tincher M, Sharma O, Wulftange W Nat Commun. 2024; 15(1):7058.

PMID: 39152149 PMC: 11329636. DOI: 10.1038/s41467-024-51014-4.


A miniaturized wash-free microfluidic assay for electrical impedance-based assessment of red blood cell-mediated microvascular occlusion.

Oshabaheebwa S, Delianides C, Patwardhan A, Evans E, Sekyonda Z, Bode A Biosens Bioelectron. 2024; 258():116352.

PMID: 38718635 PMC: 11741037. DOI: 10.1016/j.bios.2024.116352.


Rapid measurement of hemoglobin-oxygen dissociation by leveraging Bohr effect and Soret band bathochromic shift.

Sekyonda Z, An R, Goreke U, Man Y, Monchamp K, Bode A Analyst. 2024; 149(9):2561-2572.

PMID: 38501195 PMC: 11056771. DOI: 10.1039/d3an02071a.


Motion Blur Microscopy.

Goreke U, Gonzales A, Shipley B, Tincher M, Sharma O, Wulftange W bioRxiv. 2023; .

PMID: 37873474 PMC: 10592665. DOI: 10.1101/2023.10.08.561435.


Catch bonds in sickle cell disease: Shear-enhanced adhesion of red blood cells to laminin.

Goreke U, Iram S, Singh G, Dominguez-Medina S, Man Y, Bode A Biophys J. 2023; 122(12):2564-2576.

PMID: 37177783 PMC: 10323024. DOI: 10.1016/j.bpj.2023.05.010.


References
1.
Man Y, Goreke U, Kucukal E, Hill A, An R, Liu S . Leukocyte adhesion to P-selectin and the inhibitory role of Crizanlizumab in sickle cell disease: A standardized microfluidic assessment. Blood Cells Mol Dis. 2020; 83:102424. PMC: 7246173. DOI: 10.1016/j.bcmd.2020.102424. View

2.
Sadaf A, Seu K, Thaman E, Fessler R, Konstantinidis D, Bonar H . Automated Oxygen Gradient Ektacytometry: A Novel Biomarker in Sickle Cell Anemia. Front Physiol. 2021; 12:636609. PMC: 8027356. DOI: 10.3389/fphys.2021.636609. View

3.
Renoux C, Parrow N, Faes C, Joly P, Hardeman M, Tisdale J . Importance of methodological standardization for the ektacytometric measures of red blood cell deformability in sickle cell anemia. Clin Hemorheol Microcirc. 2015; 62(2):173-9. PMC: 8957396. DOI: 10.3233/CH-151979. View

4.
Carden M, Little J . Emerging disease-modifying therapies for sickle cell disease. Haematologica. 2019; 104(9):1710-1719. PMC: 6717563. DOI: 10.3324/haematol.2018.207357. View

5.
Rab M, Kanne C, Bos J, van Oirschot B, Boisson C, Houwing M . Oxygen gradient ektacytometry-derived biomarkers are associated with vaso-occlusive crises and correlate with treatment response in sickle cell disease. Am J Hematol. 2020; 96(1):E29-E32. PMC: 7756395. DOI: 10.1002/ajh.26031. View